Effectiveness and safety of nivolumab in the treatment of lung cancer patients in France: preliminary results from the real-world EVIDENS study

Autor: Fabrice Barlesi, Adrien Dixmier, Didier Debieuvre, Christophe Raspaud, Jean-Bernard Auliac, Nicolas Benoit, Pierre Bombaron, Denis Moro-Sibilot, Clarisse Audigier-Valette, Bernard Asselain, Thomas Egenod, Audrey Rabeau, Jérôme Fayette, Myriam Locatelli Sanchez, Jean-Luc Labourey, Virginie Westeel, Pauline Lamoureux, François-Emery Cotte, Victoria Allan, Melinda Daumont, Juliette Dumanoir, Dorothée Reynaud, Christophe Yannick Calvet, Nicolas Ozan, Maurice Pérol

Publikováno v: OncoImmunology, Vol 9, Iss 1 (2020)

EVIDENS is an ongoing, prospective, non-interventional study evaluating the effectiveness and safety of nivolumab in lung cancer patients in France (ClinicalTrials.gov NCT03382496). Adults with a pathologically confirmed diagnosis of lung cancer and

Externí odkaz: https://doaj.org/article/213acd05a7a34a719db64a6b6903acd4

Effectiveness and safety of nivolumab in the treatment of lung cancer patients in France: preliminary results from the real-world EVIDENS study

Autor: Pauline Lamoureux, Denis Moro-Sibilot, Thomas Egenod, P. Bombaron, Melinda Daumont, Audrey Rabeau, Adrien Dixmier, Christophe Raspaud, Nicolas Benoit, Didier Debieuvre, N. Ozan, Juliette Dumanoir, Bernard Asselain, Virginie Westeel, C. Calvet, Clarisse Audigier-Valette, Dorothee Reynaud, Victoria Allan, Fabrice Barlesi, François-Emery Cotté, Maurice Pérol, Jean-Bernard Auliac, Jérôme Fayette, Jean-Luc Labourey, Myriam Locatelli Sanchez

Publikováno v: Oncoimmunology
article-version (VoR) Version of Record
OncoImmunology, Vol 9, Iss 1 (2020)

EVIDENS is an ongoing, prospective, non-interventional study evaluating the effectiveness and safety of nivolumab in lung cancer patients in France (ClinicalTrials.gov NCT03382496). Adults with a pathologically confirmed diagnosis of lung cancer and

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7b3aa8e4cd6d1d9936466474b2b2ea83
https://pubmed.ncbi.nlm.nih.gov/33457089

Association of Occupational Pesticide Exposure With Immunochemotherapy Response and Survival Among Patients With Diffuse Large B-Cell Lymphoma

Autor: Laurence Sanhes, Isabelle Baldi, Sylvain Lamure, Sara Burcheri, Alain Saad, Agathe Waultier, Franciane Paul, Guillaume Cartron, Philippe Quittet, Quam Aquereburu, C. Defez, Jean-Luc Labourey, Carole Exbrayat, Emmanuelle Tchernonog, Daniel Donadio, Ihssen Belhadj, Pascale Fabbro-Peray, Camille Carles, Eric Jourdan

Publikováno v: JAMA Network Open
JAMA Network Open, American Medical Association, 2019, 2 (4), pp.e192093. ⟨10.1001/jamanetworkopen.2019.2093⟩

International audience; Importance: Professional use of pesticides is a risk factor for non-Hodgkin lymphoma. The main biological mechanisms of pesticides and chemotherapy are genotoxicity and reactive oxygen species generation. Cellular adaptation a

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::31e2e279c8fa62c69b686d3670a7b6ee
https://hal.umontpellier.fr/hal-02863305

Patients’ self-assessment versus investigators’ evaluation in a phase III trial in non-castrate metastatic prostate cancer (GETUG-AFU 15)

Autor: Guilhem Bousquet, Loic Mourey, Michel Soulié, Stéphane Oudard, Franck Priou, Jérôme Dauba, Claude Linassier, Ali Hasbini, Igor Latorzeff, Claude El Kouri, Florence Joly, Marjorie Baciuchka, Gael Deplanque, Christine Theodore, Brigitte Laguerre, Jean Marc Ferrero, Frederic Rolland, Ivan Krakowski, Jean Luc Labourey, Remy Delva, Gwenaelle Gravis, Patricia Marino, Philippe Beuzeboc, Jean-Pascal Machiels, Damien Pouessel, Karim Fizazi, Muriel Habibian, Benjamin Esterni, Jean-François Berdah, Christian Platini, Sylvie Zanetta, Alain Ravaud, Jean-Christophe Eymard, Etienne Suc

Publikováno v: European Journal of Cancer. 50:953-962

BACKGROUND: Toxicity, which is a key parameter in the evaluation of cancer treatments, can be underestimated by clinicians. We investigated differences between patients and physicians in reporting adverse events of androgen deprivation therapy (ADT)

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d385982630957ab88d654e85a17fa892
https://doi.org/10.1016/j.ejca.2013.11.034

Prognostic Factors for Survival in Noncastrate Metastatic Prostate Cancer: Validation of the Glass Model and Development of a Novel Simplified Prognostic Model

Autor: Claude El Kouri, Marjorie Baciuchka, Gael Deplanque, Michel Soulié, Loic Mourey, Jean-Pascal Machiels, Brigitte Laguerre, Jochen Walz, Jean-Marie Boher, Patricia Marino, Jean-Marc Ferrero, Guilhem Bousquet, Jérôme Dauba, Stéphane Oudard, Philippe Beuzeboc, Claude Linassier, Christine Theodore, Florence Joly, Ivan Krakowski, Frederic Rolland, Jean-François Berdah, Alain Ravaud, Karim Fizazi, Remy Delva, Gwenaelle Gravis, Muriel Habibian, Igor Latorzeff, Ali Hasbini, Damien Pouessel, Sylvie Zanetta, Christian Platini, Jean-Christophe Eymard, Jean-Luc Labourey, Etienne Suc, Franck Priou

Publikováno v: European Urology
European Urology, 2015, 68 (2), pp.196-204. ⟨10.1016/j.eururo.2014.09.022⟩
European Urology, Elsevier, 2015, 68 (2), pp.196-204. ⟨10.1016/j.eururo.2014.09.022⟩
European Urology, (2014)

BACKGROUND: The Glass model developed in 2003 uses prognostic factors for noncastrate metastatic prostate cancer (NCMPC) to define subgroups with good, intermediate, and poor prognosis. OBJECTIVE: To validate NCMPC risk groups in a more recently diag

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::131ce3a6a68644c9ae91a6321f02e24a
https://www.hal.inserm.fr/inserm-03353959/document